EUCTR2007-003248-31-FI进行中（未招募）不适用
An open, phase IV, non-randomised, single-centre study with two study groups to assess the immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced antigen content diphtheria-tetanus toxoids andacellular pertussis vaccine (Boostrix), when administered in young adults, 10 years after previous booster vaccination in study 263855/004 (dTpa-004). - DTPA (BOOSTRIX): 040 EXT Y10
GSK Biologicals0 个研究点开始时间: 2007年10月17日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- •Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/004 (dTpa-004) study.
- •A male or female subject, recruited 10 years (+/- 9 months) after booster vaccination in study 263855/004 (dTpa-004).
- •If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must use adequate contraception for 30 days prior to vaccination and continue for 2 months after completion of the vaccination series. Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly (when applicable, as mentioned in the product label) for example abstinence, combined or progestogen oral contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic vaginal ring, percutaneous contraceptive patches or intrauterine device (IUD) or intrauterine system (IUS), vasectomy with documented azoospermia of the sole male partner or other barrier method (condom or occlusive cap).
- •Written informed consent obtained from the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose. For corticosteroids, this will mean prednisone, or equivalent, >=0.5 mg/kg/day. Inhaled and topical steroids are allowed.
- •Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination. or planned administration during the active study period (up to Visit 2).
- •Previous booster vaccination against tetanus, diphtheria or pertussis since the last dose received in study 263855/004 (dTpa-004).
- •History of documented diphtheria, tetanus, or pertussis diseases.
- •Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination (no laboratory testing required).
研究者
相似试验
进行中（未招募）
1 期
A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine dTpa (Boostrix™) when administered in healthy adult subjects, after previous booster vaccination with dTpa in study 263855/029 (dTpa-029). - DTPA (BOOSTRIX)-041 BST 029Immune persistence and booster immunisation against diphtheria, tetanus and pertussis in adults.EUCTR2009-016012-21-BEGlaxoSmithKline Biologicals647
已完成
不适用
Study to evaluate the Safety and Efficacy of a Tacrolimus twice daily, PROGRAF® versus a Tacrolimus Modified Release, ADVAGRAF®, in stable Liver transplant recipientsKCT0000478Samsung Medical Center94
进行中（未招募）
不适用
A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellular pertussis and inactivated poliovirus vaccine dTpa-IPV (Boostrix-Polio) when administered in healthy subjects aged 9-13 years, 5 years after previous booster vaccination with dTpa-IPV in the study 711866/001 (dTpa-IPV-001). - DTPA-IPV (Boostrix-IPV): 008 Ext 001 Y5EUCTR2007-003477-94-DEGlaxoSmithKline Biologicals
进行中（未招募）
不适用
A Study to Evaluate long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-derived stabilizer) In children and adolescentsProphylaxis: Tick-borne-encephalitisEUCTR2014-005105-20-Outside-EU/EEAovartis Vaccines and Diagnostics232
招募中
4 期
A study to evaluate the safety and effectiveness of Saroglitazar 4 mg in patients with NAFLD with comorbiditiesCTRI/2023/05/053326Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)